Navigation Links
Oceanside Pharmaceuticals Announces Launch of Librax(R) AG
Date:11/23/2009

ALISO VIEJO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Oceanside Pharmaceuticals, part of Valeant Pharmaceuticals International (NYSE: VRX), today announced that it has now launched chlordiazepoxide hydrochloride and clidinium bromide, an authorized generic (AG) version of Librax®. Oceanside has received its first orders and expects to be a significant player in the Librax® generic market.

"Valeant's Oceanside unit has become an important division of our U.S. business with its successful launch and distribution of 5% fluorouracil, Valeant's authorized generic of Efudex®," stated J. Michael Pearson, chairman and chief executive officer. "Oceanside currently maintains a 55% market share of its Efudex® AG and plans to retain this leadership position in the future. With the industry experience we have had with Efudex® AG, we believe that we can successfully grow a strong market position with the launch of Librax® AG."

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Oceanside's launch and growth of Librax AG and Oceanside's strong leadership position with Efudex AG. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the U.S. Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.


Contact:
Laurie W. Little
Valeant Pharmaceuticals
949-461-6002
laurie.little@valeant.com

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)

SOURCE Valeant Pharmaceuticals International


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... May 31, 2016 ... Assembly zur Eliminierung von viraler Hepatitis    ... historische Verpflichtung eingegangen, virale Hepatitis bis 2030 zu ... World Health Assembly haben sich die Staaten einstimmig ... Hepatitis (Global Viral Hepatitis Strategy) zu verabschieden, was ...
(Date:5/30/2016)... 2016 Transparency Market Research has ... Systems Market - Global Industry Analysis, Size, Share, Growth, ... report, the global advanced (3D/4D) visualization systems market was ... anticipated to expand at a CAGR of 6.4% from ... 2024. Advanced (3D/4D) visualization systems have propelled ...
(Date:5/30/2016)... , May 30, 2016 ... "Healthcare Analytical Testing Services Market by Type (Stability, ... Services), by End User (Pharmaceutical Companies, Medical Device ... MarketsandMarkets, The market witnessed healthy growth during the ... a CAGR of 11.3% between 2016 and 2021 ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... , ... Spectrum Aquatics has launched a brand new ADA pool lift, the ... the user in mind. , “Over the last two years our key customers and ... lbs lift is a necessary requirement for certain facilities with specific needs,” said Nabil ...
(Date:5/31/2016)... ... May 31, 2016 , ... Interest is on the ... tool and as an orthogonal tool for RNAi hit validation. A key reason may ... guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. , ...
(Date:5/31/2016)... ... 2016 , ... TeaZa® Energy, LLC announces the launch of a ... Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be available to customers exclusively ... The new flavor is best described as a juicy, taste bud takeover. A ...
(Date:5/31/2016)... ... May 31, 2016 , ... MinerEye ... Vendors in Security Infrastructure Protection report by Gartner1 Inc. , Each year, Gartner ... research reports evaluating these innovative vendors and their products and services. , According ...
(Date:5/31/2016)... ... 31, 2016 , ... Advertising Age has recognized SourceLink, ... for the tenth consecutive year as a Top 20 Marketing Services Agency. Final ... ranked eighteenth in the “U.S. CRM/Direct Marketing Agency” category. , Recent investments ...
Breaking Medicine News(10 mins):